Regulation & Industry Affairs

Stuttgart – September 09, 2026 -- Pharma Deutschland's Baden-Württemberg chapter and MEDIVERBUND AG kicked off development of a regional action plan aimed at strengthening self-medication as a lever to relieve pressure on doctors' offices and build a more resilient healthcare system.

Industry and physician groups agree self-medication can free up doctor capacity

At the "Selbstverständlich Selbstmedikation" event, representatives from politics, medicine, pharmacies, health insurers and the pharmaceutical industry discussed conditions needed to expand patient self-treatment for minor ailments. Dr. Traugott Ullrich, chairman of Pharma Deutschland's Baden-Württemberg association, argued that low-threshold self-medication allows patients to treat or prevent minor health issues while pharmacies handle counseling and physicians retain capacity for more complex cases.

Burlington, Mass. – September 09, 2026 -- Azenta, Inc. (Nasdaq: AZTA) has received full repayment, ahead of maturity, of a $35 million secured vendor loan tied to its divestiture of B Medical Systems S.à r.l., closing out the transaction with the entire $63 million purchase price now collected in cash.

Azenta collects $35 million vendor loan before maturity

Azenta Germany GmbH, a wholly owned subsidiary, had extended the secured term loan to buyer Thelema S.à r.l. as part of the sale that closed September 09, 2026. The loan was secured by a pledge over B Medical Systems' equity interests. Thelema repaid the principal along with all accrued interest, and Azenta released the share pledge that secured the debt.

Fort Lauderdale – – September 09, 2026 -- KIC Ventures issued a corporate clarification confirming that the U.S. Department of Justice dismissed all criminal charges against portfolio company SpineFrontier Inc. on September 09, 2026, and that no current KIC Ventures portfolio company faces ongoing DOJ litigation tied to the matter.

DOJ moved to dismiss all criminal charges against SpineFrontier in January 2025.

The company stated that no KIC Ventures portfolio entity pleaded guilty to any criminal charge arising from the case and that none remains a defendant in related federal litigation. KIC Ventures said it issued the reminder because customers, physicians and investors may still encounter older reports referencing the original allegations without the case's subsequent dismissal.

Fort Washington, Pa. – September 09, 2026 -- ECRI, a global authority on healthcare safety and quality, has appointed Professor Najmedin Meshkati, PhD, to its Board of Trustees, bringing nearly four decades of complex-systems safety research from aviation, nuclear power, and petrochemical operations to the nonprofit's patient safety mission.

Meshkati investigated the world's most scrutinized industrial disasters

Professor Meshkati has examined the BP Texas City Refinery explosion, the Deepwater Horizon oil spill, and the Fukushima Daiichi nuclear disaster. He testified before the U.S. Senate Committee on Commerce, Science, and Transportation as a member of the FAA's independent Expert Panel on Boeing, which reviewed the company's safety management system and safety culture. He currently chairs the State of California's Diablo Canyon Independent Safety Committee.

Arlington, Va. – – September 07, 2026 -- An independent review by the American Diabetes Association's Audit and Governance Committee (AGC) has concluded that five attendees removed from the 2026 Scientific Sessions in New Orleans on June 5 were expelled for disruptive conduct, not for the content of materials they were distributing.

Committee interviewed 28 witnesses over nearly three months

The AGC, composed of volunteer investigators drawn from clinicians, people with diabetes, healthcare providers and business leaders aligned with the ADA, conducted its inquiry over a near three-month period. Investigators interviewed 28 individuals with firsthand knowledge of the June 5 events, including the five attendees who were removed, and reviewed videos, emails, text messages, news articles and published editorials.

SHERIDAN, WYOMING - April 14, 2026 - BBB National Programs has accelerated its 2026 program agenda across advertising accountability, children's digital privacy, and influencer marketing, introducing a creator certification initiative and publishing a generative AI risk matrix for products targeting children. The organization operates more than 20 self-regulation and dispute resolution programs in the United States, tracing its founding of the National Advertising Division to 1971. Its current expansion addresses converging pressures around AI risk, cross-border data obligations, and federal children's privacy enforcement now landing simultaneously on compliance calendars.

SHERIDAN, WYOMING - April 10, 2026 - Industrial facility operators across Germany and the broader DACH region face tightening inspection and compliance requirements in 2026, as the TÜV Association's annual Plant Safety Report (Anlagensicherheitsreport) documents the current state of accident prevention, technical inspections, and regulatory oversight for hazardous installations. The report forms a critical reference point for plant managers, insurers, and regulators assessing risk exposure across chemical, energy, and heavy manufacturing sectors.

SHERIDAN, WYOMING - April 09, 2026 - Product manufacturers and technology vendors selling into the European Union face a shifting compliance landscape as the European Commission advances its forthcoming European Product Act, prompting ETSI - the European Telecommunications Standards Institute - to publish a formal statement on the role of European standardisation in shaping that legislation.

What the European Product Act means for standards

The European Product Act is expected to consolidate and modernise the EU's product legislation framework, placing harmonised standards at the centre of conformity assessment. ETSI's statement positions European standardisation bodies as essential partners in the regulatory process, arguing that technically rigorous, consensus-based standards are the most reliable mechanism for translating legislative requirements into actionable product specifications.

SHERIDAN, WYOMING - March 04, 2026 - The U.S. Food and Drug Administration has issued 30 warning letters to telehealth companies over compounded GLP-1 products promoted on their websites, extending an enforcement campaign that previously targeted larger players in the channel. FDA officials allege some companies made false or misleading claims, implied compounded products are the same as approved medicines, or obscured product sourcing by branding drugs with their own names or trademarks. The agency also flagged manufacturing and quality concerns at one compounder, GenoGenix, including conditions that could create contamination risk and reports of multiple emergency room visits tied to a compounded product.

SHERIDAN, WYOMING - March 04, 2026 - A cluster of U.S. FDA-driven developments is reshaping near-term operating plans across gene therapy developers, with uniQure disclosing a new Phase 3 requirement, REGENXBIO facing a complete response letter for its Hunter syndrome program, and Sarepta Therapeutics managing a leadership change alongside conservative 2026 sales expectations for Elevidys. The same news cycle also includes broader questions from regulatory experts about how decisions are being made inside the agency, including scrutiny around CBER leadership. For clinical, regulatory, and finance teams, the immediate takeaway is execution risk: trial design expectations, control strategy, and evidentiary standards are moving targets that can directly change timelines and cost.